Shenzhen New Industries Biomedical Engineering (300832) Q2 2026 earnings summary

Executive summary

• Achieved revenue of ¥2.42 billion, up 10.78% year-over-year, and net profit attributable to shareholders of ¥867.71 million, up 12.53%.

• Domestic business showed recovery with main business revenue up 7.52% and reagent sales up 12.08% year-over-year.

• Overseas business revenue grew 15.17%, with reagent sales up 32.20% and high-end equipment sales strong.

• Continued innovation in small molecule sandwich assay technology, with related reagent revenue up 84.79%.

Financial highlights

• Operating income: ¥2.42 billion, up 10.78% year-over-year.

• Net profit attributable to shareholders: ¥867.71 million, up 12.53% year-over-year.

• Operating cash flow: ¥901.17 million, up 95.29% year-over-year.

• Basic and diluted EPS: ¥1.1057, up 12.67% year-over-year.

• Gross margin: 71.09%, up 2.45 percentage points year-over-year.

Outlook and guidance

• Will continue to focus on high-value reagents and expand market share in high-end medical terminals.

• Plans to deepen R&D in small molecule sandwich assay and automation platforms.

• Expects continued growth in overseas markets through regional and localized operations.